Glycom A/s

Societe Des Produits Nestle S.a.

Bruce McConnell

Louise Kristine Vigsnæs

Emma Elison

Gyula Dekany

Elise Champion

Thierry Hennet

David Paul Kronlage

Louise Kristine Vignæs

Norbert Sprenger

Nikolay Khanzhin

Markus Jondelius Hederos

Jonas Hauser

Francis Foata

Sami Damak

Kristine Rothaus Christensen

Nora Schneider

Louise Kristine Vigsnaes

Emma Salomonsson

Ingvild Dybdrodt Amundsen

Louise Kristine VIGSNÆS

Use of a human milk oligosaccharide (HMO), or a nutritional composition comprising a human milk oligosaccharide, to enhance executive function in a non-infant, to prevent and/or reduce the risk of sub-optimal executive function in a non-infant, to manage sub-optimal executive functioning in a non-infant, and/or to improve myelination to mature the pre-frontal cortex region of the brain in a non-infant, as well as synthetic compositions of HMOs and packs comprising at least 14 individual daily doses of an effective amount of at least one HMO for such a use.

Human milk oligosaccharides for use in enhancing executive function

A synthetic composition and method for use in providing a source of oligosaccharides to a human consuming a low-FODMAP diet, increasing the abundance of bifidobacteria in the colon of a human consuming a low-FODMAP diet, and/or reintroducing FODMAPs into the diet of a human consuming a low-FODMAP diet. The composition contains one or more human milk oligosaccharides.

Composition and method for treating humans using low-fodmap diets

A synthetic mixture of human milk oligosaccharides (HMOs) consisting essentially of lacto-N-neotetraose (LNnT), lacto-N-tetraose (LNT), 2'-fucosyllactose (2′FL), 3′-O-sialyllactose (3′-SL), 6′-O-sialyllactose (6′-SL) either difucosyllactose (DFL) or 3-fucosyllactose (3-FL), preferably DFL, and optionally lactose. Said synthetic composition is useful for: treating or preventing viral and/or bacterial infection in a non-infant human; modulating the microbiota of a non-infant human; and/or improving the cognitive function of a non-infant human and as a pharmaceutical or nutritional composition.

Mixture of HMOs

The invention relates to a synthetic composition comprising human milk oligosaccharides for use in at least partially restoring the commensal gastrointestinal microbiota and preventing or mitigating antibiotic associated diarrhoea.

Synthetic composition for treating antibiotic associated complications

The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in, and a method for the treatment of, secondary prevention of, and/or induction of tolerance to non-coeliac wheat and/or gluten sensitivity in a human.

Mixture of HMOS for treating wheat sensitivity

The invention relates to a mixture of human milk oligosaccharides and composition comprising thereof, that consists essentially of: LNnT, LNT, 2′-FL, 3′-SL, 6′-SL and either DFL or 3-FL, preferably DFL, that can be useful for preventing and/or treating viral and/or bacterial infections in a human.

Mixture of human milk oligosaccharides(HMOs)

This disclosure relates generally to compositions and methods for preventing or treating mast cell mediated visceral pain.

Composition comprising HMSs/HMOs and use thereof

The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides.

A method includes selecting a non-infant patient having an obesity-related metabolic disorder and being diagnosable with one or more of obesity, obesity-induced pre-diabetes, and obesity-induced type 2 diabetes. The method further includes selecting an effective amount of one or more human milk oligosaccharides (HMOs) selected from: fucosylated HMOs 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), lacto-N-fucopentaose I (LNFP-I), and difucosyllactose (DFL); non-fucosylated HMOs lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 3′,6-disialyllacto-N-tetraose (DSLNT), 6′-sialyllactose (6′-SL), and 3′-sialyllactose (3′-SL); and mixtures thereof. The method further includes increasing the relative abundance ofin the non-infant patient by administering the selected effective amount of the selected one or more HMOs and improving in the non-infant patient at least one condition selected from increased insulin sensitivity, reduced insulin resistance, improved gut barrier function, and reduction of metabolic inflammation. In various examples, the method includes increasing levels of at least one glucagon-like peptide.

Synthetic composition for treating metabolic disorders

The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2'-fucosyllactose (2&#x2032;-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof.

Synthetic composition and method for treating irritable bowel syndrome

A human milk oligosaccharide (HMO) or a synthetic composition comprising said HMO, for use in increasing the abundance, particularly the relative abundance, of aof thephylogenic group in the microbiota in the gastro-intestinal tract of a human, preferably a non-infant human. The HMO(s) and/or synthetic composition is useful in; increasing particularly the relative abundance ofand/or; for treating or preventing in said non-infant human with type 2 diabetes and/or obesity; an enteropathogenic infection; impaired gut barrier function and/or; an inflammation related to gastro&#xac;intestinal condition, preferably irritable bowel disease (IBD) or irritable bowel syndrome (IBS); as a nutritional composition. The HMO is a fucosylated neutral HMO, a non-fucosylated neutral HMO, or a mixture of a fucosylated and a non-fucosylated neutral HMO. The HMOs comprises 2'-fucosyllactose (preferred), 2&#x2032;-fucosyllactose (preferred), 3-fucosyllactose, difucosyllactose (preferred), lacto-N-fucopentaose, fucosyl-lacto-N-hexaose, fucosyl-para-lacto-N-hexaose, lacto-N-tetraose (preferred), lacto-N-neotetraose (preferred), lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose and para-lacto-N-neohexaose.

Synthetic composition for microbiota modulation

A synthetic composition for use in improving one or more co-morbid mental disorder symptoms of a patient with IBS, characterised in that the composition contains an effective amount of one or more neutral human milk oligosaccharides, is disclosed.

Synthetic composition and method for modulating brain function and behaviour

The invention relates to a human milk oligosaccharide (HMO) for use in, a synthetic composition comprising an HMO for use in and a method for preventing or treating migraine in a human.

Human milk oligosaccharides for treating migraine

The invention relates to a method, compounds and compositions for the secondary prevention, treatment or dietary management of symptomatic and asymptomatic non-intestinal autoimmune diseases in a non-infant human including Sjogren's syndrome and type 1 diabetes. Said method, compounds and compositions for the secondary prevention, treatment or dietary management include human milk oligosaccharide (HMO), preferably mixtures of human milk oligosaccharides selected from the group of 2'-FL, LNnT, LNT, DFL, and 6&#x2032;-SL.

Mixture of HMOs for treating autoimmune diseases

The invention relates to human milk oligosaccharides (HMO) and its use in treatment of autism spectrum disorder (ASD).

Growing community of inventors

La Tour de Peilz, Switzerland

Bruce McConnell